Almac provides a streamlined approach for pharma companies to meet the Radiolabelling requirements of Phase 1 to 3 clinical trials, signaling our intent to meet the high-quality service needs of the sector. Our capability to provide cGMP services for final drug candidates, peptides, small molecules, and advanced intermediates effectively answers the demands of the market.

Read our latest Almac Voice from Dr. Sean Kitson, Investigator of Radiochemistry, to find out more on Almac’s Radiolabelling and stable isotope labelling services for pharmaceutical companies and CROs.